Back to Search Start Over

microRNA-494 is a potential prognostic marker and inhibits cellular proliferation, migration and invasion by targeting SIRT1 in epithelial ovarian cancer.

Authors :
Aijun Yang
Xuenan Wang
Chunna Yu
Zhenzhen Jin
Lingxia Wei
Jinghe Cao
Qin Wang
Min Zhang
Lin Zhang
Lei Zhang
Cuifang Hao
Source :
Oncology Letters. Sep2017, Vol. 14 Issue 3, p3177-3184. 8p.
Publication Year :
2017

Abstract

Ovarian cancer is one of the most common types of gynecological malignancy worldwide, and is the fourth leading cause of cancer-associated mortality among women. Despite improvements in therapeutic treatments, the prognosis for epithelial ovarian cancer (EOC) remains poor, mainly due to the rapid growth and metastasis of ovarian cancer tumors. An increasing number of studies have indicated that microRNAs (miRNAs) are involved in the carcinogenesis and progression of human cancer, suggesting that miRNAs may be used in clinical prognosis and as a therapeutic target in EOC. The aim of the present study was to investigate the expression levels of miRNA-494 in EOC tissues and cell lines. The clinical significance of miRNA-494 in patients with EOC was also evaluated. The results demonstrated that miRNA-494 was significantly downregulated in EOC tissues and cell lines. Low expression levels of miRNA-494 were associated with poor prognostic features, including International Federation of Gynecology and Obstetrics stage, tumor size and lymph node metastasis. In vitro functional studies demonstrated that overexpression of miRNA-494 inhibited proliferation, migration and invasion in EOC cells. By contrast, knockdown of miRNA-494 enhanced cell growth, migration and invasion in EOC cells. Notably, sirtuin 1 (SIRT1) was identified as a direct target of miRNA-494 in EOC. Furthermore, MTT, cell migration and invasion assays verified that EOC cell proliferation, migration and invasion were completely restored with forced miRNA-494 expression and SIRT1 restoration. Together, these findings suggest that miRNA-494 is a potential prognostic marker, and may provide novel therapeutic regimens of targeted therapy for EOC. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
17921074
Volume :
14
Issue :
3
Database :
Academic Search Index
Journal :
Oncology Letters
Publication Type :
Academic Journal
Accession number :
124347160
Full Text :
https://doi.org/10.3892/ol.2017.6501